This website will offer limited functionality in this browser. We only support the recent versions of major browsers like Chrome, Firefox, Safari, and Edge.
In the September issue of Pharmaceutical Executive, Lev Gerlovin addresses four main questions that US drugmakers must answer to cope with the evolving payer landscape given rising drug prices. To read the article, click the link below.
These entities receive discounts on all eligible covered outpatient drugs. The program has expanded substantially over the years, with the number of covered...
MFN-related uncertainty is reshaping pharmaceutical launch planning by making pricing, sequencing, and forecasting decisions more interconnected and...
CRA is a proud sponsor of the Educational Symposia session titled “The Oncology Combination Therapy Dilemma: Can Today’s HTA Systems Support Tomorrow’s...
CRA is a proud sponsor of the conference. Greg Bell speaks during the session titled “Damages in Pharma & Biotech Litigation: What Courts are Accepting...
